Home > Name List By 1 > 1-235-Tumor necrosisfactor receptor (human) fusion protein with 236-467-immunoglobulin G1 (human g1-chain Fc fragment) (9CI) India

CAS No 185243-69-0 , 1-235-Tumor necrosisfactor receptor (human) fusion protein with 236-467-immunoglobulin G1 (human g1-chain Fc fragment) (9CI) Search by region : India

  • Name: 1-235-Tumor necrosisfactor receptor (human) fusion protein with 236-467-immunoglobulin G1 (human g1-chain Fc fragment) (9CI)
  • Synonyms: TNFR:Fc; Etanercept; rhu TNFR:Fc;Enbrel; TNFR-Fc;Embrel; Recombinant human TNF;1-235-Tumor necrosisfactor receptor (human) fusion protein with 236-467-immunoglobulin G1 (human g1-chain Fc fragment) (9CI);
  • CAS Registry Number:
  • Flash Point: 178.8°C
  • Boiling Point: 381.8°C at 760 mmHg
  • Density: 1.757g/cm3
  • Refractive index: 1.511
  • Flash Point: 178.8°C
  • EINECS: 230-734-9
  • Molecular Weight: 0
  • InChI: InChI=1/C4H6N4O12/c9-5(10)17-1-3(19-7(13)14)4(20-8(15)16)2-18-6(11)12/h3-4H,1-2H2/t3-,4+
  • Molecular Formula: C4H6N4O12

Related products

Select to

185243-69-0 Etanercept

  • IUPAC NAME-Enbrel MOLECULAR FORMULA-C2224H3475N621O698S36 MOLAR MASS-51234.9 g/mol
  • India Swapnroop Drugs & Pharmaceuticals [Manufacturer, Trading Company]
  • Tel: 91-240-6641875
  • Fax: 91-240-6641875
  • Address: Plot No: 04, Mayur Park Road, Harsool Aurangabad,MaharashtraIndia
Contact Supplier

Select to

1/1
References of 1-235-Tumor necrosisfactor receptor (human) fusion protein with 236-467-immunoglobulin G1 (human g1-chain Fc fragment) (9CI)
Title: Etanercept
CAS Registry Number: 185243-69-0
CAS Name: 1-235-Tumor necrosis factor receptor (human) fusion protein with 236-467-immunoglobulin G1 (human g1-chain Fc fragment)
Synonyms: human tumor necrosis factor receptor p75 Fc fusion protein; TNFR:Fc
Trademarks: Enbrel (Wyeth)
Literature References: Recombinant protein consisting of the human soluble TNF receptor p75 linked to the Fc portion of human immunoglobulin G1. Dimerizes via the cysteine residues in the Fc fragment to form an immunoglobulin-like structure. Inhibits the biological effects of tumor necrosis factor, q.v. Description of prepn and medicinal use: C. A. Smith, C. A. Jacobs, WO 9406476; eidem, US 5605690 (1994, 1997 both to Immunex). Clinical pharmacokinetics: H. Lee et al., Clin. Pharmacol. Ther. 73, 348 (2003). Clinical trial as monotherapy in plaque psoriasis: C. L. Leonardi et al., N. Engl. J. Med. 349, 2014 (2003). Review of clinical experience in rheumatoid and psoriatic arthritis: B. Goffe, J. C. Cather, J. Am. Acad. Dermatol. 49, S105-S111 (2003); S. Nanda, J. M. Bathon, Expert Opin. Pharmacother. 5, 1175-1186 (2004).
Therap-Cat: Anti-inflammatory; antipsoriatic.
Keywords: Antipsoriatic; Anti-inflammatory (Biological Response Modifier).